About EnteroMedics
EnteroMedics is a publicly listed company based in Saint Paul (United States) founded in 2002. Satiety induction through vagal nerve block. EnteroMedics has raised $62.1 million across 9 funding rounds from investors including InterWest, ONSET Ventures and Pacific Asset Partners. The company has 63 employees. EnteroMedics has completed 3 acquisitions, including BarioSurg, ReShape and ReShape Lifesciences. Its focus areas include Life Sciences, Obesity, Medical Devices and Therapeutic Devices. Its legal entity is EnteroMedics Inc. Its competitors include Aspire Bariatrics, Elira and Endosphere; 3 of its 3 listed competitors have raised funding.
Company details
EnteroMedics has developed VBLOC vagal blocking therapy, a patented therapeutic approach designed to treat a range of gastrointestinal and metabolic diseases. vBloc Therapy is delivered by a pacemaker-like device called the Maestro Rechargeable System that decreases feelings of hunger and fullness by limiting the expansion of the stomach and by reducing the frequency and intensity of stomach contractions. This is achieved by intermittently blocking the primary nerve which carries signals between the brain and stomach to regulate digestive processes. Bloc Therapy involves a minimally invasive laparoscopic procedure that preserves normal digestive system anatomy.
- Headquarters Saint Paul, United States
- Employees 63
- Stage Public
- SectorsHealthcare
- Website enteromedics.com
- Social LinkedIn
- Legal Name Enteromedics Inc
Funding Insights of EnteroMedics
EnteroMedics has successfully raised a total of $62.1M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $61 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62.1M
- Total Rounds 9
- Last Round Post-IPO — $61M
- First Round $16.9M
(Nov 2004)
- Investors Count 8
All 9 funding rounds of EnteroMedics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $61M | Post-IPO | – | – | – |
| Aug 2017 | $18.1M | Post-IPO | – | – | – |
| Dec 2016 | $18.75M | Post-IPO | – | – | – |
| May 2016 | $6M | Post-IPO | – | – | – |
| Jan 2016 | $11M | Post-IPO | – | – | – |
| Jul 2015 | $16M | Post-IPO | – | – | – |
| Feb 2009 | $15.9M | Post-IPO | – | – | – |
| Jul 2006 | $45.2M | Series C | – | InterWest Partners, ONSET Ventures | |
| Nov 2004 | $16.9M | Series B | – | – |
8 investors in total: 8 institutional.
Investors in EnteroMedics
EnteroMedics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include InterWest, ONSET Ventures and Pacific Asset Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Early stage VC firm investing in the US | onset.com | Menlo Park, United States | ||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
US Life-Sciences sectors are targeted for investment by Aberdare Ventures. | aberdare.com | San Francisco, United States | ||
| clsvc.com | ||||
Healthcare startups are accelerated by Mayo Clinic Business Accelerator. | mcbusaccel.com | Rochester, United States | ||
It serves as a hedge fund focused on multiple sectors. | 2006 | pacificassetpartners.com | San Francisco, United States | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com |
Investor details for EnteroMedics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EnteroMedics
1 people are tracked at EnteroMedics (1 in leadership); the tracked headcount is 63.
| Name | Role | Group |
|---|---|---|
Nick Ansari | Senior Vice President of Sales | Leadership |
Complete people profiles for EnteroMedics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EnteroMedics
EnteroMedics has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include BarioSurg, ReShape and ReShape Lifesciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
A dual intra-gastric balloon system is provided for weight loss. | reshapeready.com | San Clemente, United States | 2005 | Oct 2017 | $61M | |
Patented minimally invasive technologies are developed for cartilage malformation corrections. | reshapelifesciences.com | Laguna Niguel, United States | 2002 | Oct 2017 | •••• | |
Minimally invasive devices for obesity and metabolic treatment are developed. | bariosurg.com | Irvine, United States | 2009 | May 2017 | •••• |
Complete acquisition details for EnteroMedics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of EnteroMedics
7 dated milestones of EnteroMedics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded EnteroMedics is founded.
- Funding First funding round of $16.9M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires BarioSurg.
- Funding Latest funding round, Post-IPO, of $61.0M.
- Acquisition Acquires ReShape Lifesciences.
- Acquisition Acquires ReShape.
Competitors of EnteroMedics
EnteroMedics has 3 listed competitors in our database, 3 of them funded. They include Aspire Bariatrics, Elira and Endosphere.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aspirebariatrics.com | 2004 | King Of Prussia, United States | $29.44M | 7 | Aspire Bariatrics is focused on weight loss solutions. | |
| elira.com | 2004 | St. Louis, United States | $8.63M | Wearable neurostimulation devices for appetite suppression are developed by Elira. | ||
| endosphereinc.com | 2006 | Columbus, United States | $6.45M | Provides a duodenal insertable implant for effective obesity treatment. |
Detailed competitors of EnteroMedics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of EnteroMedics
Websites that share an audience with EnteroMedics (enteromedics.com).
Websites whose visitors overlap most with EnteroMedics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
tickerreport.com | tickerreport.com | 100% | #1,591,824 | – | |
| humana.com | 77% | 10.5M | #4,629 | View details | |
| orexigen.com | 34% | View details |
Top companies in Obesity
3 companies that operate in the same segment as EnteroMedics (Obesity) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Bioinformatics platform is provided for biomarkers and drug discovery. | 2015 | Vallejo, California, United States | USD 293.9 M | USD 8.99 M | 64 | |
Disease-modifying therapies for metabolic diseases are developed. | 2008 | Berkeley, California, United States | USD 385.52 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enteromedics
Complete news archive for EnteroMedics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EnteroMedics
EnteroMedics was founded in 2002 and raised its 1st funding round 2 years after it was founded.
EnteroMedics is headquartered in Saint Paul, United States. It is registered at Saint Paul, Minnesota, United States.
EnteroMedics is a funded company, having raised a total of $62.1M across 9 funding rounds to date. The company's 1st funding round was a Series B of $16.9M, raised on Nov 2004.
EnteroMedics has 63 employees.
EnteroMedics has developed VBLOC vagal blocking therapy, a patented therapeutic approach designed to treat a range of gastrointestinal and metabolic diseases. vBloc Therapy is delivered by a pacemaker-like device called the Maestro Rechargeable System that decreases feelings of hunger and fullness by limiting the expansion of the stomach and by reducing the frequency and intensity of stomach contractions. This is achieved by intermittently blocking the primary nerve which carries signals between the brain and stomach to regulate digestive processes. Bloc Therapy involves a minimally invasive laparoscopic procedure that preserves normal digestive system anatomy.
EnteroMedics's top competitors include Elira, Aspire Bariatrics and Endosphere.
EnteroMedics has made 3 acquisitions, including BarioSurg, ReShape, and ReShape Lifesciences.
EnteroMedics has 8 investors. Key investors include InterWest, ONSET Ventures, Pacific Asset Partners, Bay City Capital, and Turmeric Acquisition Corp.
EnteroMedics operates through Enteromedics Inc.